Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple questionnaire predict who will follow their treatment?

NCT ID NCT06856902

Knowledge-focused Sponsor: Technical University of Madrid Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is to see if the tool can accurately identify who needs extra support to improve adherence and health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Having the diagnosis of the pilot sites target groups described above as per clinical assessment or validated diagnosis criteria * Having the age of the pilot sites target groups described above * Having accepted to participate in the study and provided written informed consent * Having the availability to participate on all study activities Exclusion Criteria: * Individuals that do not fulfil ALL the inclusion criteria will be excluded to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer cardiovascular disorder endocrine system disorder immune system disorder neoplasm nervous system disorder Rare Diseases Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Endocrinology Inmunology Neurology Oncology Rare diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AHUS - Akershus University Hospital

    RECRUITING

    Lørenskog, Akershus, 1478, Norway

  • APDP Diabetes Portugal

    RECRUITING

    Lisbon, 1250-203, Portugal

  • FHUNJ - Fundación para la Investigación Biomédica del Hospital Infantil Universitario Niño Jesús

    RECRUITING

    Madrid, Spain

  • FIIBAP - Fundación para la Investigación e Innovación Biosanitaria de Atención Primaria

    RECRUITING

    Madrid, Spain

  • FISM - Italian Multiple Sclerosis Foundation

    RECRUITING

    Genova, Italy

  • KCRI - Kilimanjaro Clinical Research Institute

    NOT_YET_RECRUITING

    Moshi, Tanzania

  • MEDCIDS - Departamento de Medicina da Comunidade Informação e Decisão em Saúde

    RECRUITING

    Porto, Portugal

  • UDUS - Heinrich-Heine-University Duesseldorf

    RECRUITING

    Düsseldorf, Germany

  • UMCM - University Medical Center Maribor

    RECRUITING

    Maribor, Slovenia

  • WDO - World Duchenne Organization

    RECRUITING

    Veenendaal, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.